These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36660350)

  • 21. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
    J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin secretion-sensitivity index-2 could be a novel marker in the identification of the role of pancreatic iron deposition on beta-cell function in thalassemia major.
    Karadas N; Yurekli B; Bayraktaroglu S; Aydinok Y
    Endocr J; 2019 Dec; 66(12):1093-1099. PubMed ID: 31527320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
    Tripathy I; Panja A; Dolai TK; Mallick AK
    Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective.
    Li J; Wang P; Li X; Wang Q; Zhang J; Lin Y
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020029. PubMed ID: 32395218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance and β cell function in patients with β-thalassemia major.
    Ghergherehchi R; Habibzadeh A
    Hemoglobin; 2015; 39(1):69-73. PubMed ID: 25572183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of the influence of iron overload in glucose metabolism in thalassemia major patients].
    Liang LY; Lao WQ; Meng Z; Zhang LN; Hou LL; Ou H; Liu ZL; He ZW; Luo XY; Fang JP
    Zhonghua Er Ke Za Zhi; 2017 Jun; 55(6):419-422. PubMed ID: 28592008
    [No Abstract]   [Full Text] [Related]  

  • 27. Iron Overload in Patients With Heavily Transfused Sickle Cell Disease-Correlation of Serum Ferritin With Cardiac T2
    Alkindi S; Panjwani V; Al-Rahbi S; Al-Saidi K; Pathare AV
    Front Med (Lausanne); 2021; 8():731102. PubMed ID: 34760898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of Combined Impaired Fasting Glucose and Impaired Glucose Tolerance in β-Thalassemia Major: Results in 58 Patients with a Mean 7.7- year Follow-Up.
    De Sanctis V; Daar S; Soliman AT; Tzoulis P; Yassin MA; Kattamis C
    Acta Biomed; 2022 Jul; 93(3):e2022242. PubMed ID: 35775758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
    Christoforidis A; Perifanis V; Tsatra I; Vlachaki E; Athanassiou-Metaxa M
    Diabetes Res Clin Pract; 2007 Apr; 76(1):6-11. PubMed ID: 16930760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose homeostasis in Egyptian children and adolescents with β-Thalassemia major: Relationship to oxidative stress.
    Metwalley KA; El-Saied AR
    Indian J Endocrinol Metab; 2014 May; 18(3):333-9. PubMed ID: 24944927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review.
    Li J; Lin Y; Li X; Zhang J
    Mediterr J Hematol Infect Dis; 2019; 11(1):e2019036. PubMed ID: 31308912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
    Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J
    Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.
    Hassan MA; Tolba OA
    Electron Physician; 2016 May; 8(5):2425-31. PubMed ID: 27382454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
    Tanous O; Azulay Y; Halevy R; Dujovny T; Swartz N; Colodner R; Koren A; Levin C
    BMC Nephrol; 2021 Dec; 22(1):418. PubMed ID: 34930156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR; Delhikumar CG; Ram Kumar G
    Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
    Zachariah M; Tony S; Bashir W; Al Rawas A; Wali Y; Pathare A
    Pediatr Hematol Oncol; 2013 Mar; 30(2):104-12. PubMed ID: 23363369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.